drugset / Trial / NCT03980522
A Pilot Study of KPL-914 in Recurrent Pericarditis
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the preliminary efficacy and safety of KPL-914 treatment in participants with recurrent pericarditis.
Timeline
- Start
- 2018-01-24
- Primary completion
- 2019-05-17
- Completion
- 2019-05-17
Publications
- Results Klein AL, Lin D, Cremer PC, Nasir S, Luis SA, Abbate A, Ertel A, LeWinter M, Beutler A, Fang F, Paolini JF. Efficacy and safety of rilonacept for recurrent pericarditis: results from a phase II clinical trial. Heart. 2020 Nov 23;107(6):488-96. doi: 10.1136/heartjnl-2020-317928. Online ahead of print.
- Lin D, Klein A, Cella D, Beutler A, Fang F, Magestro M, Cremer P, LeWinter MM, Luis SA, Abbate A, Ertel A, Litcher-Kelly L, Klooster B, Paolini JF. Health-related quality of life in patients with recurrent pericarditis: results from a phase 2 study of rilonacept. BMC Cardiovasc Disord. 2021 Apr 21;21(1):201. doi: 10.1186/s12872-021-02008-3.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rilonacept | Protein / enzyme biologic | 4.4 mg/kg | Subcutaneous |
| Subject | Rilonacept | Protein / enzyme biologic | 160 mg | Subcutaneous |